A Tool for Predicting the Success of First-Line Antiretroviral - PowerPoint PPT Presentation

A Tool for Predicting the Success of First-Line Antiretroviral Therapies Alejandro Pironti Computational Biology and Applied Algorithmics Max Planck Institute for Informatics May 19, 2011

Motivation • The first antiretroviral regimen: – Best chance of sustained virological suppression – Selection under consideration of transmitted drug resistance – Simplicity and side effects also important for success Primary Drug Resistance Trends in the RESINA Cohort 20 Prevalence(%) 15 10 5 0 2001 2002 2003 2004 2005 2006 2007 2008 Year Alejandro Pironti May 19, 2011

Motivation • Available tools for assisting therapy selection: – Designed for therapy-experienced patients – Therapy-naïve patients: • Different mutations, e.g. T215Y → T215S • A subset of regimens Alejandro Pironti May 19, 2011

The Data • 2074 first-line antiretroviral therapies from EuResist and the RESINA cohort including: – Drug compounds Histogram of Drug Combinations Alejandro Pironti May 19, 2011

The Data • 2074 first-line antiretroviral therapies from EuResist and the RESINA cohort including: – PR and RT sequences – A viral load measurement for week 48 (37-59) after therapy start or an earlier one if therapy failed before Alejandro Pironti May 19, 2011

Dichotomization • Failure: 60 – VL > 50 cp/ml at week 48 50 (37-59) – Therapy stop before week 40 48 % 30 • Definition yielded – 1188 (57%) successes 20 – 886 (43%) failures 10 • Development set: 1854 0 therapies Virological Failure at Week 48 • Test set: 220 therapies Other Failure Success Alejandro Pironti May 19, 2011

Prediction Schematic Representation of • Linear support vector a Support Vector Machine machine was used to predict therapy success n i g r a M • Training with development set • Features: – Genotype – Drug combination – Interactions up to 3 rd order, e.g. mutation:mutation:drug Hyperplane • Feature selection: z-score ≥ 2 Alejandro Pironti May 19, 2011

Performance Evolutionary Engine (therapy-experienced Therapy-Naïve Tool tool) 10 CV Development Set (AUC=0.7739) Therapy-Experienced Set (AUC=0.7650) 5-fold cross-validation on Test Set (AUC=0.7647) Therapy-Naïve Set (AUC=0.4842) Test set. AUC = 0.7110 development set. AUC = 0.7135 True Positive Rate True Positive Rate False Positive Rate False Positive Rate Alejandro Pironti May 19, 2011

Selected Features • 438 out of 8090 features selected or included by default • Default features: – WHO Mutations for Surveillance of Transmitted Drug Resistance – Drug Combination • Selected features: – PR Mutations: 4S, 10I, 12K, 13V, 15L, 19I, 20R, 37D/T, 41K, 57K, 61D/H, 63Q/N/H, 64M, 67E, 74A, 82I – RT Mutations: 39A, 162A/G, 166I, 169D, 176S, 179D/I, 192N, 200A, 207G – 140 Drug-Mutation and 190 Drug-Drug Interactions Mutations for which also a literature reference could be found Alejandro Pironti May 19, 2011

Tool Development Status • Tool and web interface have been implemented • Tool will be part of geno2pheno[resistance] • Release scheduled together with geno2pheno[resistance]’s upgrade from 3.2 to 3.3. • http://www.geno2pheno.org Alejandro Pironti May 19, 2011

Example 1 • Patient with viral mutations: – PR: 3I, 37N, 57K, 63P, 65D, 77I – RT: 60I, 67N, 69D, 122K, RT: 60I, 65R, 67N, 69D, 122K, 135T, 178I/M, 214F, 245Q, 135T, 178M, 181C, 190S, 214F, 248D, 272A, 286A, 288S, 245Q, 248D, 272A, 286A, 288S, 296S, 297K, 311K/R 296S, 297K • FLART: 3TC+ABC+EFV • Reached a VL of 56 cp/ml after 4 months of therapy. However, 2 months later, his VL went up to 4.6 log. He was switched to 3TC+ABC+FPV/r after which his VL was promptly suppressed. Drug resistance mutations Alejandro Pironti May 19, 2011

May 19, 2011 Example 1 Alejandro Pironti

Example 2 • Patient with viral mutations: – PR: 3I, 37N, 39A, 41K, 60E, 63P, 71T, 77I, 93L – RT: 123E, 135V, 162C, 169D, 207E, 214F, 245M • FLART: 3TC+AZT+EFV • After 9 months of therapy the patient still had a residual viral load of 135 cp/ml. The patient’s therapy was switched to 3TC+ABC+EFV after which the patient’s viral load became undetectable. Alejandro Pironti May 19, 2011

Example 2 Sucessful, second-line ART Originally selected FLART Alejandro Pironti May 19, 2011

Outlook • Inclusion of Darunavir • Use of – Gag mutations – HLA types for prediction improvement Alejandro Pironti May 19, 2011

Acknowledgements University of Cologne Max-Planck-Institut für Informatik Rolf Kaiser Thomas Lengauer Marc Oette André Altmann Melanie Balduin Joachim Büch Saleta Sierra Aragon Alexander Thielen Finja Schweizer Elena Knops Maria Neumann-Fraune University of Erlangen Eugen Schülter Hauke Walter Eva Heger Claudia Müller Institut für Immunologie und University of Düsseldorf Genetik Kaiserslautern Björn Jensen Martin Däumer Alejandro Pironti May 19, 2011